162 related articles for article (PubMed ID: 32992343)
21. A Paradoxical Tumor-Suppressor Role for the Rac1 Exchange Factor Vav1 in T Cell Acute Lymphoblastic Leukemia.
Robles-Valero J; Lorenzo-Martín LF; Menacho-Márquez M; Fernández-Pisonero I; Abad A; Camós M; Toribio ML; Espinosa L; Bigas A; Bustelo XR
Cancer Cell; 2017 Nov; 32(5):608-623.e9. PubMed ID: 29136506
[TBL] [Abstract][Full Text] [Related]
22. Flesh and blood: the story of Vav1, a gene that signals in hematopoietic cells but can be transforming in human malignancies.
Katzav S
Cancer Lett; 2007 Oct; 255(2):241-54. PubMed ID: 17590270
[TBL] [Abstract][Full Text] [Related]
23. A non-transgenic mouse model for B-cell lymphoma: in vivo infection of p53-null bone marrow progenitors by a Myc retrovirus is sufficient for tumorigenesis.
Yu D; Thomas-Tikhonenko A
Oncogene; 2002 Mar; 21(12):1922-7. PubMed ID: 11896625
[TBL] [Abstract][Full Text] [Related]
24. Vav1: A Dr. Jekyll and Mr. Hyde protein--good for the hematopoietic system, bad for cancer.
Katzav S
Oncotarget; 2015 Oct; 6(30):28731-42. PubMed ID: 26353933
[TBL] [Abstract][Full Text] [Related]
25. Multistep tumorigenesis in peripheral T cell lymphoma.
Sakata-Yanagimoto M
Int J Hematol; 2015 Nov; 102(5):523-7. PubMed ID: 25628103
[TBL] [Abstract][Full Text] [Related]
26. Vav1 mutations: What makes them oncogenic?
Farago M; Yarnitzky T; Shalom B; Katzav S
Cell Signal; 2020 Jan; 65():109438. PubMed ID: 31654719
[TBL] [Abstract][Full Text] [Related]
27. Vav1 Promotes B-Cell Lymphoma Development.
Shalom B; Farago M; Salaymeh Y; Sebban S; Pikarsky E; Katzav S
Cells; 2022 Mar; 11(6):. PubMed ID: 35326399
[TBL] [Abstract][Full Text] [Related]
28. Strongly reduced alloreactivity and long-term survival times of cardiac allografts in Vav1- and Vav1/Vav2-knockout mice.
Weckbecker G; Bruns C; Fischer KD; Heusser C; Li J; Metzler B; Morris RE; Nuesslein-Hildesheim B; Raulf F; Wieczorek G; Zenke G
Transpl Int; 2007 Apr; 20(4):353-64. PubMed ID: 17326776
[TBL] [Abstract][Full Text] [Related]
29. Vav1 GEF activity is required for T cell mediated allograft rejection.
Haubert D; Li J; Saveliev A; Calzascia T; Sutter E; Metzler B; Kaiser D; Tybulewicz VL; Weckbecker G
Transpl Immunol; 2012 Jun; 26(4):212-9. PubMed ID: 22456277
[TBL] [Abstract][Full Text] [Related]
30. MYC levels govern hematopoietic tumor type and latency in transgenic mice.
Smith DP; Bath ML; Metcalf D; Harris AW; Cory S
Blood; 2006 Jul; 108(2):653-61. PubMed ID: 16537801
[TBL] [Abstract][Full Text] [Related]
31. Human Vav1 expression in hematopoietic and cancer cell lines is regulated by c-Myb and by CpG methylation.
Ilan L; Katzav S
PLoS One; 2012; 7(1):e29939. PubMed ID: 22253833
[TBL] [Abstract][Full Text] [Related]
32. Vav1 accelerates Ras-driven lung cancer and modulates its tumor microenvironment.
Shalom B; Farago M; Salaymeh Y; Sebban S; Risling M; Pikarsky E; Katzav S
Cell Signal; 2022 Sep; 97():110395. PubMed ID: 35752351
[TBL] [Abstract][Full Text] [Related]
33. Vav1-mediated scaffolding interactions stabilize SLP-76 microclusters and contribute to antigen-dependent T cell responses.
Sylvain NR; Nguyen K; Bunnell SC
Sci Signal; 2011 Mar; 4(163):ra14. PubMed ID: 21386095
[TBL] [Abstract][Full Text] [Related]
34. Impaired T-cell development in the absence of Vav1 and Itk.
Raberger J; Boucheron N; Sakaguchi S; Penninger JM; Ellmeier W
Eur J Immunol; 2008 Dec; 38(12):3530-42. PubMed ID: 19009524
[TBL] [Abstract][Full Text] [Related]
35. Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis.
Hanel W; Marchenko N; Xu S; Yu SX; Weng W; Moll U
Cell Death Differ; 2013 Jul; 20(7):898-909. PubMed ID: 23538418
[TBL] [Abstract][Full Text] [Related]
36. High Expression of VAV Gene Family Predicts Poor Prognosis of Acute Myeloid Leukemia.
Mu D; Long S; Guo L; Liu W
Technol Cancer Res Treat; 2021; 20():15330338211065877. PubMed ID: 34894858
[No Abstract] [Full Text] [Related]
37. Oncogenic c-Myc-induced lymphomagenesis is inhibited non-redundantly by the p19Arf-Mdm2-p53 and RP-Mdm2-p53 pathways.
Meng X; Carlson NR; Dong J; Zhang Y
Oncogene; 2015 Nov; 34(46):5709-17. PubMed ID: 25823025
[TBL] [Abstract][Full Text] [Related]
38. Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas.
Vasmatzis G; Johnson SH; Knudson RA; Ketterling RP; Braggio E; Fonseca R; Viswanatha DS; Law ME; Kip NS; Ozsan N; Grebe SK; Frederick LA; Eckloff BW; Thompson EA; Kadin ME; Milosevic D; Porcher JC; Asmann YW; Smith DI; Kovtun IV; Ansell SM; Dogan A; Feldman AL
Blood; 2012 Sep; 120(11):2280-9. PubMed ID: 22855598
[TBL] [Abstract][Full Text] [Related]
39. A Natural Variant of the Signaling Molecule Vav1 Enhances Susceptibility to Myasthenia Gravis and Influences the T Cell Receptor Repertoire.
Bernard I; Sacquin A; Kassem S; Benamar M; Colacios C; Gador M; Pérals C; Fazilleau N; Saoudi A
Front Immunol; 2018; 9():2399. PubMed ID: 30410484
[TBL] [Abstract][Full Text] [Related]
40. Vav1 increases Bcl-2 expression by selective activation of Rac2-Akt in leukemia T cells.
Wan YJ; Yang Y; Leng QL; Lan B; Jia HY; Liu YH; Zhang CZ; Cao Y
Cell Signal; 2014 Oct; 26(10):2202-9. PubMed ID: 24880064
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
